Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)

Chromadex Corp (OTCMKTS: CDXC) and Mesoblast Limited (NASDAQ:MESO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Insider & Institutional Ownership

3.0% of Mesoblast Limited shares are held by institutional investors. 18.8% of Mesoblast Limited shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Chromadex Corp and Mesoblast Limited, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex Corp 0 0 3 0 3.00
Mesoblast Limited 0 2 4 0 2.67

Chromadex Corp presently has a consensus target price of $6.33, suggesting a potential upside of 51.88%. Mesoblast Limited has a consensus target price of $14.25, suggesting a potential upside of 111.42%. Given Mesoblast Limited’s higher probable upside, analysts plainly believe Mesoblast Limited is more favorable than Chromadex Corp.

Profitability

This table compares Chromadex Corp and Mesoblast Limited’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex Corp -52.09% -63.19% -41.08%
Mesoblast Limited -3,184.70% -14.79% -11.55%

Valuation & Earnings

This table compares Chromadex Corp and Mesoblast Limited’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Chromadex Corp $20.41 million 9.42 -$6.27 million N/A N/A
Mesoblast Limited $2.41 million 263.22 -$86.99 million ($0.96) -7.02

Chromadex Corp has higher revenue and earnings than Mesoblast Limited.

Summary

Mesoblast Limited beats Chromadex Corp on 7 of the 11 factors compared between the two stocks.

Chromadex Corp Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Mesoblast Limited Company Profile

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

What are top analysts saying about Chromadex Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chromadex Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit